Download MendeleyTargeting the Class A Carbapenemase GES-5 via Virtual Screening.
Klein, R., Cendron, L., Montanari, M., Bellio, P., Celenza, G., Maso, L., Tondi, D., Brenk, R.(2020) Biomolecules 10
- PubMed: 32075131 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.3390/biom10020304
- Primary Citation Related Structures:
6TS9 - PubMed Abstract:
The worldwide spread of β-lactamases able to hydrolyze last resort carbapenems contributes to the antibiotic resistance problem and menaces the successful antimicrobial treatment of clinically relevant pathogens. Class A carbapenemases include members of the KPC and GES families. While drugs against KPC-type carbapenemases have recently been approved, for GES-type enzymes, no inhibitors have yet been introduced in therapy. Thus, GES carbapenemases represent important drug targets. Here, we present an in silico screening against the most prevalent GES carbapenemase, GES-5, using a lead-like compound library of commercially available compounds. The most promising candidates were selected for in vitro validation in biochemical assays against recombinant GES-5 leading to four derivatives active as high micromolar competitive inhibitors. For the best inhibitors, the ability to inhibit KPC-2 was also evaluated. The discovered inhibitors constitute promising starting points for hit to lead optimization.
- Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, 55122 Mainz, Germany.
Organizational Affiliation:
